Novan — Investor Presentation (January 2019)
29 slides from Novan's investor presentation, Jan 7, 2019
Slide 1: Corporate Overview
Exhibit 99.2 January 2019 Corporate Overview
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our plans to develop and commercialize our product candidates, including our interpretation of preclinical and clinical studies and the success and tim
Slide 3: Core Technology Platform Based on Nitric Oxide
Core Technology Platform Based on Nitric Oxide ▪ Naturally produced nitric oxide has diverse biological activity within the body − Immunology (bacterial, viral and inflammatory responses) − Cardiology/pulmonology (vasodilation/hemostasis, anti-coagulation, and respiration) − Neurology (neurotransmit
Slide 4: Novan's Nitric Oxide Technology Platform
Novan’s Nitric Oxide Technology Platform First macromolecular platform to achieve stable, tunable and druggable delivery of nitric oxide: Stable Tunable Druggable New Chemical Entity (NCE) Novan has created a proprietary platform enabling development of NCEs with Proprietary formulations, Multiple d
Slide 5: Experienced Leadership Team
Experienced Leadership Team Alignment of significant scientific and drug development expertise to Novan’s short, intermediate and longer-term opportunities Robert A. Ingram G. Kelly Martin Executive Chairman Chief Executive Officer Paula Brown Stafford Carri Geer, PhD President and Chief Operating O
Slide 6: Clinical Progress Made Since Q4 of 2017
Clinical Progress Made Since Q4 of 2017 Oct-17: SB414 (Psoriasis) Ph 1b Dec-18: SB206 Trial Initiation Aug-18: SB414 (Molluscum) Ph 2 Full (Psoriasis & Atopic Dermatitis) Top Line Results Dec-17: SB414 Ph 1b Clinical Results (Atopic Dermatitis) Ph 1b Trial Initiation Nov-18: SB206 Jan-18: SB206 (Mol
Slide 7: Focused Dermatology Development Pipeline
Focused Dermatology Development Pipeline Product Indication Preclinical Phase 1 Phase 2 Phase 3 Candidates SB204 Acne Vulgaris SB206 Molluscum SB414 Atopic Dermatitis ▪ Acne Vulgaris (Multifactorial1): Successful in 1 of 2 Phase 3 pivotal trials ▪ Molluscum (Antiviral): Positive Phase 2 results with
Slide 8: Corporate Progress Made Over the Past Months
Corporate Progress Made Over the Past 12 Months Oct-18: Strategic Alliance with Orion Provides Extension of Jan-19: Strengthens and Jan-18: Closing Technical Production Capacity Aligns Management Team, of $38.0M GI Diseases Added as Field Financing of Focus Oct-18: Formation Feb-18: Formation of of
Slide 9: Value Creation Opportunities Over the Past Months
Value Creation Opportunities Over the Past 12 Months ▪ Sato/Japan amendment to include SB206: EGW and molluscum1 − ~$11M of upfront non-dilutive cash inflows; payable in installments through 3Q 2019 − Further potential milestone and royalty payments ▪ Multiple geographic business development discuss
Slide 10: Nitric Oxide Platform Expansion: Women's Health & Gastroenterology
Nitric Oxide Platform Expansion: Women’s Health & Gastroenterology Women’s Health Gastroenterology ▪ Novan’s nitric oxide technology has demonstrated the ▪ Inherent connection between the multi-factorial ability to inhibit HPV amplification and replication in pathologies of GI diseases and the demon
Slide 11: Molluscum Contagiosum Overview
Molluscum Contagiosum Overview Molluscum is a contagious skin infection caused by the ▪ Prevalence of ~6 million in the US1,2 molluscipoxvirus, a double- − ~1 million diagnosed annually stranded DNA virus − ~90% of patients below the age of 18 ▪ Typically present with 10-30 lesions, up to 100 in sev
Slide 12: Anti-Viral Mechanism of Action
Anti-Viral Mechanism of Action ▪ Multiple publications show nitric oxide inhibits viral replication via S-nitrosylation in the following viruses: − Human papillomavirus (HPV): double-stranded DNA virus − Herpes simplex virus (HSV): double-stranded DNA virus − Coxsackievirus: single-stranded RNA viru
Slide 13: Molluscum Contagiosum Current Treatment Landscape
Molluscum Contagiosum Current Treatment Landscape Choice of 1st Line Description Side-Effects/Limitations Treatment1 Physical ▪ Curettage, cryotherapy, laser ▪ Pain, anxiety, burning, 29% Therapies surgery erythema, dyspigmentation ▪ Applied with wooden end of ▪ Blistering agent cotton-tipped swab 2
Slide 14: Phase 2 Study of SB206 in the Treatment of Molluscum
Phase 2 Study of SB206 in the Treatment of Molluscum A Phase 2, multi-center, randomized, double-blind, vehicle-controlled, ascending dose study of SB206 in subjects with molluscum contagiosum Cohort 3 Cohort 4 12% BID (n=47) 12% QD (n=48) Cohort 2 Vehicle (n=17) Vehicle (n=16) 8% BID (n=48) Cohort
Slide 15: SB206 Phase 2 Disposition & Demographics
SB206 Phase 2 Disposition & Demographics Vehicle All SB206 SB206 12% QD Randomized, N1 66 190 48 Completed study visits and treatment 60 (90.9%) 156 (82.1%) 43 (89.6%) Age, mean (range) 7.0 (2 - 16) 6.9 (2 – 62) 5.7 (2 - 11) Baseline lesion count, mean 18.3 19.3 17.6 Randomization was stratified by
Slide 16: SB206 Phase 2 Primary Endpoint: Complete Clearance of All Lesions
SB206 Phase 2 Primary Endpoint: Complete Clearance of All Lesions mITT Population ITT Population 60 60 50 * * 50 * 40 40 30 30 % Responders (SE) Responders % 20 (SE) Responders % 20 10 10 0 0 Week 1 Week 2 Week 4 Week 8 Week 12 Week 1 Week 2 Week 4 Week 8 Week 12 Vehicle 4% BID 8% BID 12% BID 12% QD
Slide 17: SB206 Phase 2 Secondary Endpoints
SB206 Phase 2 Secondary Endpoints Clearance of ≥75% Lesions (mITT) Percent Change from Baseline Lesion Count (mITT) 70 20 * 60 * * 10 * * 0 50 -10 * 40 -20 -30 * 30 * * * -40 * % Responders (SE) Responders % 20 -50 * -60 * 10 Adj.Mean(SE) % ChangefromBaseline, -70 * 0 -80 Week 1 Week 2 Week 4 Week 8
Slide 18: SB206 Phase 2 Safety and Tolerability
SB206 Phase 2 Safety and Tolerability (Safety Population) Vehicle All SB206 SB206 12% QD (N=66) (N=188) (N=47) Subjects who discontinued treatment due to adverse events (AEs) 0 7 (3.7%) 0 AEs leading to treatment discontinuation (subjects) Application site reaction (pain, erythema) 0 6 0 Worsening m
Slide 19: Summary of SB206 Phase 2 Top Line Results
Summary of SB206 Phase 2 Top Line Results ▪ Higher rates of complete clearance of all molluscum lesions at Week 12 for the three highest doses, 8% twice-daily, 12% twice-daily and 12% once- daily, more than double the rate observed in the vehicle group ▪ Statistically significant reductions in mollu
Slide 20: SB206 for the Treatment of Molluscum Path Forward
SB206 for the Treatment of Molluscum Path Forward ▪ Novan has requested an end-of-Phase 2 meeting with the FDA − This meeting would enable Novan and the FDA to agree on a Phase 3 development plan for molluscum with SB206 12% once-daily as the active treatment arm ▪ Following a successful end-of-Phas
Slide 21: SB204 as a Potential Treatment for Acne Vulgaris
SB204 as a Potential Treatment for Acne Vulgaris ▪ In 2Q 2018, conducted a Type C meeting; focus was on the severe patient population ▪ In 3Q 2018, the FDA provided feedback in their minutes on two paths forward: − One additional pivotal trial for moderate-to-severe acne patients, or − Additional pr
Slide 22: Confirmatory SB204 Phase 3 Clinical Trial Optimizations
Confirmatory SB204 Phase 3 Clinical Trial Optimizations ▪ We have executed a business arrangement with a specialized- dermatology Contract Research Organization (CRO) for trial start-up activities ▪ Trial Optimizations: − Increased patient density per clinical site relative to NI-AC301 or NI- AC302
Slide 23: Atopic Dermatitis Overview
Atopic Dermatitis Overview ▪ ~22M Americans suffer from mild-to- moderate AD1 − ~80% of disease burden ▪ Typically patients are treated first line with topical therapies − Corticosteroids, calcineurin inhibitors and PDE4 inhibitors ▪ Nitric oxide targets the NLRP3 inflammasome and has the ability to
Slide 24: Mean Perceived Efficacy/Safety of Atopic Dermatitis Treatments
Mean Perceived Efficacy/Safety of Atopic Dermatitis Treatments 7.0 6.0 High-Potency Topical Biologics Corticosteroids (e.g. IL-13/IL-4 inhibitors) JAK/SYK 5.0 Inhibitors SB414 Mid-Potency Topical Target Corticosteroids 4.0 Product Profile Perceived Efficacy Perceived More Favorable Efficacy Favorabl
Slide 25: SB414 Phase 1b Trial Design for Atopic Dermatitis
SB414 Phase 1b Trial Design for Atopic Dermatitis Trial Design pH Restoring Hydrogel 6% SB414 Cream Adults with Mild to 2% SB414 Cream Moderate Atopic Dermatitis Vehicle Cream n = 48 BID, 2 week treatment duration NVN1000 Ointment Self-emulsifying Randomized, double-blind, vehicle-controlled Phase 1
Slide 26: SB414 Phase 1b Atopic Dermatitis Trial Results
SB414 Phase 1b Atopic Dermatitis Trial Results Vehicle SB414 2% SB414 6% (N=14) (N=17) (N=17) Fold Change in Biomarkers over Vehicle at Wk 2 IL-4R - -2.5* -1.7 IL-5 - -7.1* -4.2 Confirmation of IL-13 - -10.5* -3.6 key biomarker downregulation IL-17A - -7.4* -1.0 IL-22 - -7.5* -1.8 Eczema Area and Se
Slide 27: Cross Study Comparison of Atopic Dermatitis Biomarkers
Cross Study Comparison of Atopic Dermatitis Biomarkers SB414 2% reduced key atopic dermatitis biomarkers to near non-lesional levels in 2 weeks of treatment Inflamm. Betamethasone Biomarker Vehicle1 Pimecrolimus 1%2 Non-Lesional Skin SB414 2%1 Pathway dipropionate 0.05%2 IL-4R N/A N/A IL-5 Th2 IL-13
Slide 28: Financial Update
Financial Update ▪ Cash balance at September 30, 2018 was $12.2 million ▪ Cash on hand along with the upfront payments expected from the Sato Amendment anticipated to provide a cash runway into late 2Q 2019 ▪ Operating model adjustments from fixed infrastructure to variable activities and costs, inc
Slide 29: Previous Months Objectives and Results
Previous 12 Months Objectives and Results Corporate Clinical o Further strengthened o Finalize SB204 (acne) business management team and board construct and clinical/regulatory o Execute on business pathway development interest around o SB206 (molluscum) Phase 2 platform and across trial top line re